 Tyme Technologies Inc. TYME, -5.56 , a biotech developing cancer metabolism-based treatments, said Tuesday its board has decided to explore its strategic options and has hired Moelis Co. as a financial adviser and Faegre Drinker Biddle Reath LLP as its legal adviser. The move comes after the Bedminster, New Jersey-based company had to discontinue a Phase 23 trial of SM-88 in combination with methoxsalen, phenytoin, and sirolimus MPS for patients with metastatic pancreatic cancer after the trial sponsor terminated the study arm due to futility. 